Biocon
Market cap ₹53,849 Cr
- P/E
- 97.28
- Day range
- ₹321.30 – ₹329.80
- 52-week range
- ₹318.40 – ₹447.15
- Volume
- 30.57 L
- Open
- ₹323.00
- Prev close
- ₹323.50
Latest results · Q1 FY27(consolidated)Revenue ₹4,336 Cr+10.0%Profit ₹137 Cr+53.4%Margin 3.2%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
BIOCON in NSE indices and F&O
F&O margin for one lot of BIOCON (2,500 shares)Research profile
Composite 47 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.0%
- Graham no.
- ₹146.39
- vs Graham
- -55.5%
- ROE ÷ P/B
- 0.9%
- 12-1 mom.
- +10.8%
- Return / vol
- -0.32
- Magic Formula
- #603
- Piotroski
- 3/6
- FCF yield
- 0.2%
Appears in 13 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.17 L Cr | 34.52 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.40 L Cr | 82.12 | 14.18 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.73 L Cr | 76.86 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.16 L Cr | 25.86 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.13 L Cr | 53.97 | 11.73 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Laurus LabsLAURUSLABS | ₹1.11 L Cr | 101.77 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| CiplaCIPLA | ₹1.09 L Cr | 32.49 | 3.14 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| BioconBIOCON | ₹53,849 Cr | 97.28 | 1.54 | 1.3% | 4.0% | 20.0% | 0.45 | +10.0% |
| Sector median | ₹24,447 Cr | 41.53 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 16d agoHeadlines about Biocon from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 72.5
- EPS (TTM)
- ₹3.38
- Price / Book
- 1.57
- ROE (FY26)
- 1.3%
- ROCE (latest year)
- 4%
- Dividend yield
- 0.15%
Moving averages (NSE)
- 20-day
- ₹356.92
- Price below
- 50-day
- ₹384.45
- Price below
- 200-day
- ₹392
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
- Others
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 12 Jun 2019: earlier bars are per pre-bonus share.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 |
| Expenses | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,176 | 3,460 | 3,340 | 3,496 | 3,489 |
| Operating Profit | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 766 | 835 | 834 | 1,020 | 847 |
| OPM % | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% | 19% | 20% | 23% | 20% |
| Other Income | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 62 | 81 | -176 | -28 | 41 |
| Interest | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 |
| Depreciation | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 |
| Profit before tax | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 | 248 | 128 |
| Tax % | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% | 22% | -24% | 20% | -7% |
| Net Profit | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 | 199 | 137 |
| EPS in Rs | ₹1.05 | ₹5.50 | ₹1.13 | ₹5.49 | ₹-0.13 | ₹0.21 | ₹2.87 | ₹0.23 | ₹0.63 | ₹1.08 | ₹0.78 | ₹0.87 |
From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+52 days since Mar 2021
+86 days since Mar 2021
+188 days since Mar 2021
-49 days since Mar 2021
-25 days since Mar 2021
Strengths, risks & growth
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
Strengths
None flagged by the checklist.
Risks
- Company has low interest coverage ratio.
- Company has a low return on equity of 3.49% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 10.9% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -16.0%
Compounded Sales Growth
- 10 Years
- +18%
- 5 Years
- +19%
- 3 Years
- +15%
- TTM
- +10%
Compounded Profit Growth
- 10 Years
- +1%
- 5 Years
- -12%
- 3 Years
- -15%
- TTM
- +100%
Stock Price CAGR
- 10 Years
- +8%
- 5 Years
- -1%
- 3 Years
- +13%
- 1 Year
- -10%
Return on Equity
- 10 Years
- +6%
- 5 Years
- +4%
- 3 Years
- +3%
- Last Year
- +1%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 54.45% | 44.91% | 44.68% | 44.68% | 0.00 pp |
| FII | 7.39% | 7.52% | 8.14% | 8.64% | +0.50 pp |
| DII | 21.67% | 24.01% | 23.33% | 29.22% | +5.89 pp |
| Government | 0.03% | 0.05% | 0.05% | 0.08% | +0.03 pp |
| Public | 16.34% | 23.40% | 23.75% | 17.20% | -6.55 pp |
| Others | 0.12% | 0.09% | 0.05% | 0.19% | +0.14 pp |
Filed with NSE for Sept 2026: promoters 44.68%, public 55.14% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 22.12% (+6.64 pp)- Promoters44.8%
- Foreign institutions8.7%
- Mutual funds22.1%
- Insurance5.6%
- Other domestic institutions1.7%
- Retail5.9%
- Others11.3%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| SBI Contra Fund | 2.61% | 3.29% | -0.25 pp |
| SBI Large & Midcap Fund | 1.64% | 2.20% | +0.16 pp |
| Kotak Mid Cap Fund | 1.21% | 1.03% | +1.03 pp |
| SBI Midcap Fund | 1.02% | 2.48% | -0.22 pp |
| ICICI Pru Focused Fund | 0.85% | 2.69% | +2.69 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- Avg
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 25.5%
- Downside volatility
- 26.1%
- Worst 5% of days
- 2.5%
- Average of that tail
- 3.6%
- Max drawdown (1Y)
- 26.6%
- Below its peak
- 26.6%
Against the market
- Beta vs Nifty 50
- 0.72
- Correlation
- 0.38
- Relative strength (3M)
- -20.3%
- ATR (14)
- 2.8%
Return
- Return 1M
- -17.1%
- Return 3M
- -25.7%
- Return 6M
- -9.6%
- Return 1Y
- -8.1%
- vs 200-day average
- -17.5%
Momentum
- RSI (14) · oversold
- 18.2
- MACD histogram
- -2.00
- Stochastic %K
- 9.3
- ADX (14)
- 47.4
- +DI / −DI
- 7.4 / 44.0
- Money flow index
- 19.4
Participation
- Delivery (20d avg)
- 53.1%
- vs its 60-day baseline
- +1.2 pts
- Volume vs 20-day
- +1.1σ
- Close vs day's VWAP
- +0.1%
- 52-week position
- 0 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
3 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹82 Cr
- FCF yield
- 0.2%
- Cash conversion
- 5.41
- Accruals ratio
- -0.026
- Net debt
- ₹13,018 Cr
- Net debt / equity
- 0.38
- EV / sales
- 3.81
- Capex intensity
- 11.3%
- Revenue CAGR
- 2.3%
- Profit CAGR
- -56.8%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividendNot available — not reported in this filing
Dividend - Re 0.50 Per Share
3 Jul 2026ex-date - dividend₹0.50
Dividend - Rs 0.50 Per Share
4 Jul 2025ex-date - dividendNot available — not reported in this filing
Dividend - Re 0.50 Per Share
5 Jul 2024ex-date - dividend₹1.50
Dividend - Rs 1.50 Per Share
7 Jul 2023ex-date - dividend₹0.50
Dividend - Rs 0.50 Per Share
30 Jun 2022ex-date - dividend₹0.50
Dividend - Rs 0.50 Per Share
18 Jul 2019ex-date - bonusNot available — not reported in this filing
Bonus 1:1
12 Jun 2019ex-date - dividendNot available — not reported in this filing
Dividend- Re 1 Per Share
19 Jul 2018ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 1/- Per Share
20 Jul 2017ex-date - bonusNot available — not reported in this filing
Bonus 2:1
15 Jun 2017ex-date - otherNot available — not reported in this filing
Annual General Meeting
22 Jun 2016ex-date - dividend₹5.00
Interim Dividend - Rs 5/- Per Share (Purpose Revised)
17 Mar 2016ex-date - otherNot available — not reported in this filing
Annual General Meeting
16 Jul 2015ex-date - dividend₹5.00
Interim Dividend Rs 5/- Per Share
9 Apr 2015ex-date - dividend₹5.00
Annual General Meeting / Final Dividend - Rs 5/- Per Share
10 Jul 2014ex-date - dividend₹5.00
Annual General Meeting/Final Dividend Rs 5/- Per Share + Special Dividend Rs 2.5/- Per Share
11 Jul 2013ex-date - dividend₹5.00
Annual General Meeting / Dividend Rs 5 Per Share
5 Jul 2012ex-date - dividend₹3.00
Annual General Meeting/Dividend Rs 3 Per Share
7 Jul 2011ex-date - dividend₹1.50
Interim Dividend-Rs.1.50 Per Share (Purpose Revised)
5 May 2011ex-date - dividend₹3.50
Annual General Meeting And Dividend Rs.3.50 Per Share
8 Jul 2010ex-date
Company announcements
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Disclosure pursuant to Regulation 30 of SEBI Listing Regulations
Grant of Employee Stock Options
Intimation regarding closure of Trading Window
Press Release
Communication regarding remittance of final dividend for the FY 2025-26
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Press Release
Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)
Communication regarding remittance of final dividend for the FY 2025-26
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mylan Inc.
Filed with BSE (scrip 532523); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Order
Order in respect of Mr. Kunal Kashyap and Allegro Capital Pvt. Ltd. in the matter of Biocon Ltd.
8 Jul 2021Read on SEBI - Order
Order in respect of Mr. Shreehas P Tambe in the matter of Biocon Ltd. [SAT Appeal No.: 491/2021]
30 Jun 2021Read on SEBI - Adjudication order
Adjudication Order in respect of Narendra Chirmule and Biocon Ltd., in the matter of Biocon Ltd.,
19 May 2021Read on SEBI - Final order
Final Order in the matter of Biocon Limited
5 May 2021Read on SEBI - Adjudication order
Adjudication Order in respect of Mr. P. Ravishankar in the matter of Biocon Limited
28 Oct 2020Read on SEBI
Documents
Annual reports
Earnings calls
- Aug 2026TranscriptRecording
- Jun 2026TranscriptSlides
- May 2026Slides
- Feb 2026TranscriptSlides
- Feb 2026Slides
- Dec 2025Slides
Credit ratings
- Rating update · 16 Dec 2025 from crisil
- Rating update · 16 Dec 2025 from icra
- Rating update · 9 Dec 2025 from fitch
- Rating update · 30 Oct 2025 from icra
- Rating update · 17 Jun 2025 from crisil
- Rating update · 22 Jan 2025 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 5 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Biocon: common questions
Answered from the figures on this page.
